Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple …
Background Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell
transplantation is standard treatment in Europe for transplant-eligible patients with newly …
transplantation is standard treatment in Europe for transplant-eligible patients with newly …
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple …
P Moreau, M Attal, C Hulin, B Arnulf… - Lancet (London …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell
transplantation is standard treatment in Europe for transplant-eligible patients with newly …
transplantation is standard treatment in Europe for transplant-eligible patients with newly …
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple …
P Moreau, M Attal, C Hulin, B Arnulf… - The …, 2019 - researchinformation.amsterdamumc …
Background: Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell
transplantation is standard treatment in Europe for transplant-eligible patients with newly …
transplantation is standard treatment in Europe for transplant-eligible patients with newly …
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple …
P Moreau, M Attal, C Hulin, B Arnulf, K Belhadj… - The Lancet, 2019 - research.rug.nl
BACKGROUND: Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-
cell transplantation is standard treatment in Europe for transplant-eligible patients with newly …
cell transplantation is standard treatment in Europe for transplant-eligible patients with newly …
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple …
P Moreau, M Attal, C Hulin, B Arnulf, K Belhadj… - Lancet, 2019 - dial.uclouvain.be
(eng) BACKGROUND: Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous
stem-cell transplantation is standard treatment in Europe for transplant-eligible patients with …
stem-cell transplantation is standard treatment in Europe for transplant-eligible patients with …
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple …
P Moreau, M Attal, C Hulin, B Arnulf… - Lancet (London …, 2019 - europepmc.org
Background Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell
transplantation is standard treatment in Europe for transplant-eligible patients with newly …
transplantation is standard treatment in Europe for transplant-eligible patients with newly …
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple …
P Moreau, M Attal, C Hulin, B Arnulf, K Belhadj… - The Lancet, 2019 - repub.eur.nl
Background Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell
transplantation is standard treatment in Europe for transplant-eligible patients with newly …
transplantation is standard treatment in Europe for transplant-eligible patients with newly …
[引用][C] Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple …
P Moreau, N Meuleman - Lancet, 2019 - difusion.ulb.ac.be
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple …
P Moreau, M Attal, M Roussel, C Hulin, B Arnulf… - The Lancet, 2019 - elibrary.ru
All patients provided written informed consent. The trial was done in accordance with the
principles of the Declaration of Helsinki and the International Conference on Harmonisation …
principles of the Declaration of Helsinki and the International Conference on Harmonisation …
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple …
P Moreau, M Attal, C Hulin, B Arnulf, K Belhadj… - The Lancet, 2019 - hal.science
Background Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell
transplantation is standard treatment in Europe for transplant-eligible patients with newly …
transplantation is standard treatment in Europe for transplant-eligible patients with newly …